سعر فولفيلا 6 مجم/0.6 مل سرنجة معبأة 2025

Pegfilgrastim (a biosimilar long-acting G-CSF) 6 mg/0.6 ml solution for subcutaneous injection in a single prefilled syringe, listed in Egypt under One Pharma Medics.

• To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Not indicated for mobilisation of peripheral blood progenitor cells.Population: Patients with non-myeloid malignancies on myelosuppressive chemotherapyDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (at least 5% more than placebo): bone pain and pain in extremity.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of serious allergic reactions to pegfilgrastim or filgrastim products (reactions have included anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Splenic rupture, including fatal cases: evaluate patients with left upper abdominal or shoulder pain. Acute respiratory distress syndrome: evaluate fever, lung infiltrates or respiratory distress and discontinue if ARDS. Serious allergic reactions including anaphylaxis: permanently discontinue. Fatal sickle cell crises in sickle cell disorders. Glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, and MDS/AML in breast and lung cancer patients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Data with pegfilgrastim products in pregnant women are insufficient to establish a drug-associated risk; published filgrastim data have not shown an association with major birth defects, miscarriage or adverse outcomes. In rabbits, embryolethality and abortions occurred at 4 times the maximum human dose with maternal toxicity.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on pegfilgrastim in human milk; other filgrastim products are poorly secreted into milk and not absorbed orally by neonates. Weigh benefits of breastfeeding against the mother's need for the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pegfilgrastim: Covalent conjugate of recombinant methionyl human G-CSF with a 20 kD monomethoxypolyethylene glycol; acts on haematopoietic cells to stimulate neutrophil production (US Fulphila label).